Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Roche Inks Discovery, Development Pacts

by Rick Mullin
June 15, 2009 | A version of this story appeared in Volume 87, Issue 24

Roche and Raptor Pharmaceuticals have entered a collaborative research agreement in which Roche will fund studies of the therapeutic delivery of select molecules across the blood-brain barrier (BBB) using Raptor's proprietary NeuroTrans BBB transporter platform. The agreement grants Roche exclusive worldwide license to NeuroTrans for use in delivering therapeutic and diagnostic molecules. Roche also signed a collaboration agreement with SeqWright, a DNA-sequencing firm, and the University of Miami's Miller School of Medicine to identify possible genetic variants associated with dilated cardiomyopathy, a disease of the heart muscle. Financial terms were not disclosed.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.